Proven Cardiovascular Benefits Reduced major adverse cardiovascular events (MACE) Reduced heart failure risk Anti-atherosclerotic effects Blood pressure reduction Weight-mediated cardiometabolic improvement Semaglutide and liraglutide especially demonstrated major cardiovascular outcome benefits
Elevated SAH may add a second barrier by inhibiting methylation even when methyl donors are present
Watch for Lipohypertrophy Repeatedly injecting into the same spot can cause lumps of fatty tissue to form under the skin (lipohypertrophy)
So, what makes glutathione the master antioxidant
Tirzepatide is a newer, dual-action medication that works on GLP-1 and a second pathway (GIP), which is why many patients see even greater results
Upstream of Cys, S can be channeled to 5-phosphoadenosine 3-phosphate, 5-phosphoadenosine 3-phosphosulfate, and secondary compounds such as glucosinolates in the Brassicaceae (Fig